Boston Scientific
BSX
$46.73
+1.59%
Boston Scientific Corp. is a global medical device company specializing in less invasive technologies for interventional cardiology, cardiac rhythm management, endoscopy, urology, and neuromodulation. As a diversified leader in the medical devices industry, it competes with firms like Medtronic and Abbott, with a strong presence in high-growth segments such as cardiovascular and medsurg. The current investor narrative centers on the company's strategic $1.5 billion investment in MiRus to enter the transcatheter aortic valve replacement (TAVR) market, which has generated significant analyst attention despite recent stock price declines. Debate persists around the timing of this investment amid a broader market sell-off and underwhelming clinical trial results, but the long-term growth opportunity in aortic stenosis treatment remains a key catalyst.…
BSX
Boston Scientific
$46.73
Related headlines
BSX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $64.28 and implied upside of +37.5% versus the current price.
Average Target
$64.28
0 analysts
Implied Upside
+37.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$50 - $94
Analyst target range
Boston Scientific is covered by 28 analysts, with a consensus recommendation of 'strong_buy' (mean rating 1.5 on a 1-5 scale). The average target price is $72.43, implying 63.7% upside from the current price of $44.25. The distribution leans heavily bullish, with no sell ratings evident from the institutional ratings data, which shows repeated 'Buy' and 'Outperform' actions from firms like Mizuho, RBC Capital, Needham, and Jefferies. The target range spans from a low of $55.00 to a high of $106.00, indicating significant conviction in the stock's recovery. The high target of $106 assumes a return to prior highs, likely driven by successful TAVR market entry and margin expansion, while the low target of $55 still implies 24.3% upside, suggesting even the most bearish analyst sees value. Recent ratings have been uniformly positive, with no downgrades in the past two months, reinforcing bullish sentiment. The wide spread between low and high targets ($51) reflects uncertainty around the timing and magnitude of the recovery, but the overall consensus is strongly bullish, with analysts betting on the company's growth catalysts and current depressed valuation.
Drowning in data?
Find the real signal!
BSX Technical Analysis
Boston Scientific is in a deep downtrend, with the stock price falling 58.3% over the past year, significantly underperforming the S&P 500's gain of 16.5%. The current price of $44.25 sits at just 40.4% of its 52-week range (low $42.2, high $109.5), indicating the stock is near its lows. This positioning suggests either a potential value opportunity if fundamentals stabilize or a falling knife if negative momentum persists, as the stock has not shown signs of bottoming yet. Short-term momentum remains negative, with a 1-month decline of 47.2% and a 3-month decline of 28.7%, both far worse than the S&P 500's respective gains of 0.8% and 3.5%. The relative strength index (RSI) is not provided, but the consistent downward price action and volume data (average volume 20.6 million shares) suggest continued selling pressure. The divergence between the 1-month and 1-year trends is minimal, as both are deeply negative, reinforcing the bearish trend rather than signaling a reversal. Key support is at the 52-week low of $42.2, while resistance is at the 52-week high of $109.5. A breakdown below $42.2 could trigger further downside, while a breakout above $109.5 would require a massive reversal. The stock's beta of 0.577 indicates it is less volatile than the market, meaning the 58% decline is particularly severe relative to its typical risk profile, and the stock may be experiencing company-specific headwinds rather than broad market factors.
Beta
0.58
0.58x market volatility
Max Drawdown
-60.6%
Largest decline past year
52-Week Range
$42-$110
Price range past year
Annual Return
-55.5%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | +8.5% | +0.2% |
| 3m | -17.3% | +3.7% |
| 6m | -50.0% | +8.0% |
| 1y | -55.5% | +18.2% |
| ytd | -50.7% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Revenue growth has been solid, with Q1 2026 revenue of $5.203 billion up 11.6% year-over-year, accelerating from the 10.8% growth in Q1 2025. The trailing twelve-month revenue is approximately $20.6 billion, driven by the Cardiovascular segment ($3.493 billion in Q1) and MedSurg ($1.814 billion). The multi-quarter trend shows consistent growth, with revenue rising from $4.12 billion in Q2 2024 to $5.203 billion in Q1 2026, indicating a healthy trajectory. However, the recent stock decline suggests investors are concerned about future growth sustainability or margin pressures. Profitability is strong, with Q1 2026 net income of $1.337 billion and a net margin of 25.7%, up from 14.5% in Q1 2025. Gross margin improved to 69.4% from 63.3% a year ago, reflecting better cost management or product mix. Operating margin also expanded to 20.6% from 19.2%, indicating operational efficiency. The company is clearly profitable and generating robust earnings, which supports its ability to invest in growth initiatives like the MiRus deal. The balance sheet is healthy, with a debt-to-equity ratio of 0.51 and a current ratio of 1.62, indicating adequate liquidity. Free cash flow for the trailing twelve months is $3.442 billion, providing ample internal funding for investments and reducing reliance on external financing. Return on equity (ROE) is 11.9%, and return on assets (ROA) is 6.1%, both reasonable for the medical device industry. The company does not pay dividends, instead reinvesting cash into growth and acquisitions, which aligns with its strategy.
Quarterly Revenue
$5.2B
2026-03
Revenue YoY Growth
+11.6%
YoY Comparison
Gross Margin
69.4%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 48.6x, while the forward P/E is 11.9x, a massive gap that implies the market expects significant earnings growth in the coming year. This forward multiple is based on estimated EPS of $5.195, which would represent a dramatic increase from the trailing EPS of $0.91 (based on the most recent quarterly EPS of $0.9 annualized). The gap suggests the market is pricing in a sharp recovery or one-time charges distorting trailing earnings. Compared to the industry average (not provided), the stock's P/S ratio of 7.0x is elevated relative to the medical devices sector, which typically trades around 3-5x sales. The EV/EBITDA of 29.7x also suggests a premium valuation. This premium may be justified by the company's strong growth, high margins, and market leadership, but it also leaves little room for error. Historically, the trailing P/E has ranged from 17.4x (Q1 2026) to 189.3x (Q4 2021), with the current 48.6x near the middle of that range. The forward P/E of 11.9x is near the low end of historical forward multiples, suggesting that if earnings materialize as expected, the stock could be undervalued. However, the wide dispersion between trailing and forward earnings raises questions about the sustainability of the earnings jump.
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~88x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple
